Aug 2026· Journal of Gene Medicine· Vol 28· 0 citations· 28 references
Medicine
TL;DR
This work identifies circFut8—a conserved exonic circRNA originating from FUT8 gene exon 3—as a bc tumor suppressor, which is significantly downregulated in bc tissues and cell lines, correlating with advanced tumor grade and invasion.
Abstract
Circular RNAs (circRNAs) represent key regulators in cancer pathogenesis; however, their involvement in alternative splicing (AS) remains poorly understood.
Findings indicate that circ_0001495 may serve as a potential diagnostic/prognostic biomarker for BCa and promotes tumor progression by activating the miR-1184/MAPK signaling axis.
A specific protein (SRSF2) acts like a rogue editor, altering the genetic instructions of another molecule (hnRNPD) and creates a “shield” (PD-L1) on the surface of the cancer cell, effectively blinding the immune system and allowing the tumor to grow unchecked.
Zhao Cheng, Lin Jiang, Ming-yang Wang et al.· Oncogene· 0 citations
A tumor oncogenic function of circBRWD3 is uncovered in NSCLC through the regulation of TRIM25 protein stability and miR-135a-5p/miR-135b-5p/SPTBN2 axis.
Yan-Hua Zhu, Yue-Feng He, Mei Xiao et al.· Cell Death and Disease· 0 citations
Circular RNAs (circRNAs) exhibit wide expression across human tissues and play pivotal roles in tumorigenesis and cancer progression. However, studies regarding the function and mechanism of circRNAs in lung adenocarcinoma (LUAD) are insufficient, it needs to be further explored. This investigation aimes to describe dy...
Peini Xue, Yong-Heng Gao, Tianhao Li et al.· Experimental Cell Research· 0 citations
The data suggest that circPRKCA may act as a scaffold for RNA-binding proteins (RBPs), potentially facilitating the recruitment of SRSF1 to HIF-1A mRNA, which appeared to correlate with increased HIF-1A stability, and reveal novel diagnostic biomarkers and therapeutic strategies for NSCLC.
Hai-Ting Chen, Xing-Xing Jin, Leilei Tao et al.· Experimental Cell Research· 0 citations
The findings establish circEVI5 as a novel oncogenic driver that facilitates RCC progression through the miR-433/GBP2 regulatory axis and provides a framework for developing RNA-based therapies.
Yang Xiong, Jin Li, Zhi-Peng Tang et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
